Medicenna Reports Preclinical MDNA209 Results in Autoimmune Disease Models
Medicenna reported CD122 blockade and extended survival with MDNA209 in preclinical autoimmune disease models.
Medicenna reported CD122 blockade and extended survival with MDNA209 in preclinical autoimmune disease models.